Clinical trial · Observational
The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular Carcinoma
NCT05088811CI-TRIAL-00054616unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this work is to study the role of long non-coding RNAs WRAP53 and urothelial carcinoma-associated 1 (UCA1) as potential biomarkers in diagnosis of hepatocellular carcinoma.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diagnoses Disease | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Liver Cirrhosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| WRAP53, UCA-1 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Liver cirrhosis
- description
- Group (1): Thirty patients having liver cirrhosis and hepatocellular carcinoma diagnosed by tripahsic CT.
- interventionNames
- Diagnostic Test: WRAP53, UCA-1
- label
- Hepatocellular Carcinoma
- description
- Group (2): Thirty liver cirrhosis patients without hepatocellular carcinoma diagnosed by abdominal ultrasound examination
- interventionNames
- Diagnostic Test: WRAP53, UCA-1
- label
- Control
- description
- Group (3): Twenty normal subjects (control group) matching in age and sex with patients in groups 1 and 2.
- interventionNames
- Diagnostic Test: WRAP53, UCA-1
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Any subject without any of the exclusion criteria Exclusion Criteria: * Patients with any inflammatory diseases or other malignancies.
References
Publications (4)
- RESULTKamel MM, Matboli M, Sallam M, Montasser IF, Saad AS, El-Tawdi AHF. Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma. Transl Res. 2016 Feb;168:134-145. doi: 10.1016/j.trsl.2015.10.002. Epub 2015 Oct 24. PMID 26551349
- RESULTPouladi N, Abdolahi S, Farajzadeh D, Hosseinpour Feizi MA. Haplotype and linkage disequilibrium of TP53-WRAP53 locus in Iranian-Azeri women with breast cancer. PLoS One. 2019 Aug 6;14(8):e0220727. doi: 10.1371/journal.pone.0220727. eCollection 2019. PMID 31387111
- RESULTWang F, Ying HQ, He BS, Pan YQ, Deng QW, Sun HL, Chen J, Liu X, Wang SK. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget. 2015 Apr 10;6(10):7899-917. doi: 10.18632/oncotarget.3219. PMID 25760077
- DERIVEDAbdelmoety AA, Elhassafy MY, Said RSO, Elsheaita A, Mahmoud MM. The role of UCA1 and WRAP53 in diagnosis of hepatocellular carcinoma: A single-center case-control study. Clin Exp Hepatol. 2023 Jun;9(2):129-137. doi: 10.5114/ceh.2023.127569. Epub 2023 Jun 18. PMID 37502440